- Home
- Services
- usa california
- cancer risk mouse study
Show results for
Refine by
Cancer Risk Mouse Study Services In Usa California
5 services found
Manufactured by:Grail, Inc. based inMenlo Park, CALIFORNIA (USA)
Assessing the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. The PATHFINDER Study is a prospective, multi-center study that will evaluate the implementation of GRAIL’s multi-cancer early detection test into clinical practice. GRAIL’s test is designed to detect and localize multiple types of cancer through a single blood draw, with a very ...
Manufactured by:Grail, Inc. based inMenlo Park, CALIFORNIA (USA)
Evaluation of a New Blood Test for Detecting Multiple Types of Cancer Early. The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 25,000 men and women age 50 to 77 years who do not have a cancer diagnosis at the time of enrollment. SUMMIT aims to further evaluate GRAIL’s blood ...
Manufactured by:Grail, Inc. based inMenlo Park, CALIFORNIA (USA)
Mapping the Landscape of Genomic Cancer Signals in the Blood. The Circulating Cell-free Genome Atlas (CCGA) Study is a prospective, observational, longitudinal, study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study has enrolled approximately 15,000 participants across 142 sites in the United States and Canada, and includes ...
by:xCures based inOakland, CALIFORNIA (USA)
xCures’ patient-centric focus ensures that advanced cancer patients continuously engage with the xCures platform. Patients and their treating physicians receive decision support and access to leading therapeutics and diagnostics in return for ongoing access to their electronic medical records throughout their cancer journey. This direct patient engagement yields continuous, prospective Real ...
Manufactured by:XILIS, Inc. based inDurham, NORTH CAROLINA (USA)
Xilis’ rapid and scalable patient-derived MicroOrganoSphere (MOS) technology platform enhances precision medicine and pharmaceutical drug discovery and development. Compared to conventional patient-derived models, MOS provides faster, higher-throughput, and greater cost savings, as well as more predictive and accurate results. MOS can be used in large-scale pharmacogenomic studies that are ...